Startups
Bambusa Therapeutics is a rapidly growing biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, Bambusa's mission is to advance the field of immunology with cutting-edge solutions.
Overview
Location
United States
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 23
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 19, 2026 | Bambusa Therapeutics Presents Detailed BBT001 Atopic Dermatitis Proof-of-Concept Results at ISAD 2026 | Detailed findings from a randomized, double-blind, placebo-controlled cohort presented by Eric Simpson, M.D., M.C.R., of Oregon Health & Science University Presentation brings previously announced clinical findings together with pharmac... |
| Oct 1, 2026 | Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data | First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31 High-concentration subcutaneous formulation designed to combine BBT001's emerging profile of rapid, deep a... |
| Jul 27, 2026 | Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential | BBT001 delivered highly statistically significant and clinically meaningful improvement in EASI beginning at Week 1, with responses continuing to improve over time Fast-onset and potent itch relief was observed as early as Day 1 after the f... |
| Jul 15, 2026 | Bambusa Therapeutics Appoints Howard Liang, Ph.D. to its Board of Directors and Establishes Scientific Advisory Board | Dr. Liang brings deep biopharma finance, strategy, and capital markets expertise to support the company's next phase of growth Bambusa also forms a Scientific Advisory Board of globally recognized leaders in biopharma, dermatology, and... |
| Jun 15, 2026 | Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 | - BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - BBT002 demonstrated rapid, deep, and sustained biomarker effects through at least 8 weeks follow... |
| May 18, 2026 | Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial | - BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - Preliminary Phase 1 data demonstrated rapid, deep, and sustained effects on key biomarkers for a... |
| Apr 30, 2026 | Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis | - Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 ... |
| Apr 1, 2026 | Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting | - Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 ... |
| Mar 19, 2026 | Bambusa Therapeutics Appoints Todd James Chief Financial Officer | - Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at Acceleron Pharma prior to its $11.5 b... |
Show more
Reviews 0
FAQ about Bambusa Therapeutics
What has the press written about Bambusa Therapeutics?
Parsers VC has collected 23 articles mentioning Bambusa Therapeutics, among them “Bambusa Therapeutics Presents Detailed BBT001 Atopic Dermatitis Proof-of-Concept Results at ISAD 2026” (Oct 19, 2026) and “Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data” (Oct 1, 2026).
Is Bambusa Therapeutics still active?
Bambusa Therapeutics is probably closed: its latest activity on Parsers VC dates from Oct 30, 2026.